ATE500266T1 - Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine - Google Patents

Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine

Info

Publication number
ATE500266T1
ATE500266T1 AT04735139T AT04735139T ATE500266T1 AT E500266 T1 ATE500266 T1 AT E500266T1 AT 04735139 T AT04735139 T AT 04735139T AT 04735139 T AT04735139 T AT 04735139T AT E500266 T1 ATE500266 T1 AT E500266T1
Authority
AT
Austria
Prior art keywords
protein variant
biological response
effectiveness
improving
host cell
Prior art date
Application number
AT04735139T
Other languages
English (en)
Inventor
Yong-Hoon Chung
Hak-Sup Lee
Ki-Wan Yi
Youn-Hwa Heo
Jae-Youn Kim
Original Assignee
Medexgen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medexgen Co Ltd filed Critical Medexgen Co Ltd
Application granted granted Critical
Publication of ATE500266T1 publication Critical patent/ATE500266T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT04735139T 2003-07-26 2004-05-27 Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine ATE500266T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030051846A KR100632985B1 (ko) 2003-07-26 2003-07-26 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
PCT/KR2004/001246 WO2005010043A1 (en) 2003-07-26 2004-05-27 A method of improving efficacy of biological response-modifying proteins and the exemplary muteins

Publications (1)

Publication Number Publication Date
ATE500266T1 true ATE500266T1 (de) 2011-03-15

Family

ID=36284112

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04735139T ATE500266T1 (de) 2003-07-26 2004-05-27 Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine

Country Status (14)

Country Link
US (3) US7569361B2 (de)
EP (1) EP1668030B1 (de)
JP (1) JP4747238B2 (de)
KR (1) KR100632985B1 (de)
CN (2) CN102286090A (de)
AT (1) ATE500266T1 (de)
AU (1) AU2004259314B2 (de)
BR (1) BRPI0412607A (de)
CA (1) CA2528458A1 (de)
DE (1) DE602004031642D1 (de)
ES (1) ES2362453T3 (de)
RU (1) RU2432360C2 (de)
WO (1) WO2005010043A1 (de)
ZA (1) ZA200600502B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2006120580A2 (en) * 2005-05-04 2006-11-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
EP2009103A1 (de) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophische Peptide
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
KR101510743B1 (ko) 2013-07-23 2015-04-10 (주)케어젠 파골 세포 분화 억제용 펩타이드 및 이의 용도
US10052343B1 (en) * 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
EP3596108A4 (de) 2017-03-15 2020-12-23 Pandion Operations, Inc. Gezielte immuntoleranz
KR101947342B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Gm-csf 반감기를 증가시키는 방법
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
WO2021146436A2 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
EP4107187A4 (de) 2020-02-21 2024-07-03 Pandion Operations, Inc. Gewebegezielte immuntoleranz mit einem cd39-effektor
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
EP4617281A1 (de) * 2022-11-10 2025-09-17 Kanglitai Biomedical (Qingdao) Co., Ltd. Ortsspezifisches pegyliertes heteromeres protein oder polypeptid sowie herstellungsverfahren dafür und verwendung davon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
CN1057534C (zh) * 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
AU3538799A (en) * 1998-04-30 1999-11-23 Kirin Brewery Company, Limited Human thrombopoietin mutants
DK1578772T3 (da) * 2002-05-01 2010-08-16 Danisco Us Inc Cytokiner og cytokinreceptorer med reduceret immunogenicitet

Also Published As

Publication number Publication date
US20100041586A1 (en) 2010-02-18
KR100632985B1 (ko) 2006-10-11
KR20050013024A (ko) 2005-02-02
EP1668030B1 (de) 2011-03-02
JP4747238B2 (ja) 2011-08-17
BRPI0412607A (pt) 2007-07-03
EP1668030A4 (de) 2006-06-14
CA2528458A1 (en) 2005-02-03
JP2007524403A (ja) 2007-08-30
ZA200600502B (en) 2007-02-28
CN101384620B (zh) 2011-08-17
EP1668030A1 (de) 2006-06-14
WO2005010043A1 (en) 2005-02-03
CN101384620A (zh) 2009-03-11
AU2004259314B2 (en) 2006-12-07
RU2006102846A (ru) 2007-09-10
US7569361B2 (en) 2009-08-04
DE602004031642D1 (de) 2011-04-14
RU2432360C2 (ru) 2011-10-27
US20130089513A1 (en) 2013-04-11
CN102286090A (zh) 2011-12-21
US20060008872A1 (en) 2006-01-12
ES2362453T3 (es) 2011-07-05
AU2004259314A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
ATE500266T1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
WO2006014349A3 (en) Method of producing fully carbamylated erythropoietin
MXPA05014215A (es) Mapeo de genoma de elementos funcionales de adn y proteinas celulares.
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA021222B8 (ru) Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
PT973794E (pt) Receptores de netrina
Białkowska et al. Extremophilic proteases as novel and efficient tools in short peptide synthesis
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
DE69826493D1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
ATE532863T1 (de) Verfahren zur anzucht von myokardzellen
Hanson et al. Design of MHC class II (DR4) ligands using conformationally restricted imino acids at p3 and p5
AU2001289034A1 (en) Novel pdes and uses thereof
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
DE69826717D1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
WO1997014966B1 (en) Method of activating a novel ligand regulatory pathway
DE60032161D1 (de) P-glycoproteine und ihre verwendungen
Antonyan et al. Proline-rich cytokine from neurosecretory granules: A new natural substrate for dipeptidyl peptidase IV
DE60312497D1 (de) Verwendung von protein maba (fabg1) aus mycobacterium tuberculosis zur herstellung und nachweis von antibiotika

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties